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resonance. Peripheral plasma levels of 21 miRNAs were assessed by quantitative real-time polymerase chain
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bloodstream: the circulating levels of both cardiac- and non–cardiac-speciﬁc miRNAs are signiﬁcantly increased in
the plasma of HCM patients. However, correlation with left ventricular hypertrophy parameters holds true for only
a few miRNAs (i.e., miR-199a-5p, -27a, and -29a), whereas only miR-29a is signiﬁcantly associated with both
hypertrophy and ﬁbrosis, identifying it as a potential biomarker for myocardial remodeling assessment in HCM.
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921(4). One of the hallmarks of HCM is myocardial remodeling,
characterized by cardiomyocyte hypertrophy, sarcomeric
disarray, and ﬁbrosis (1–3).
Several studies have demonstrated a functional role of mi-
croribonucleic acid (miRNA) in myocardial hypertrophy
(5–8). These small, noncoding ribonucleic acids (RNAs)
function as post-transcriptional regulators of gene expres-
sion, modulating several physiological and pathological
processes. In the heart, they have a crucial role in physio-
logical development, hypertrophy, ischemia/reperfusion in-
jury, angiogenesis, atherosclerosis, apoptosis, and ﬁbrosis. In
animal models of hypertrophy, miRNAs were found to be
up-regulated, down-regulated, or unchanged in comparison
with the levels measured in normal hearts (9).
Since the discovery of their presence also in the blood-
stream (10), miRNAs have attracted interest as putative cir-
culating biomarkers of cardiovascular disease (11): distinctive
proﬁles of circulating miRNAs have been reported for acute
myocardial infarction (12), heart failure (13), coronary artery
disease (14), and diabetes mellitus (15). However, whether
HCM is accompanied by a speciﬁc circulating miRNA
signature is still not known.
We thus aimed to characterize the circulating miRNA
proﬁle of HCM, evaluating 21 miRNAs directly involved in
angiogenesis, ﬁbrosis, apoptosis, hypertrophy, and smooth
muscle cell biology (Online Table 1). Moreover, we assessed
the correlation with the degree of left ventricle (LV)
hypertrophy, as evaluated by transthoracic echocardiography
(TTE) and cardiac magnetic resonance (CMR). We found
that 12 circulating miRNAs were signiﬁcantly increased in
HCM patients with respect to healthy age- and sex-
matched subjects, but only 3 of these miRNAs (miR-27a,
-29a, and -199a-5p) correlated with cardiac hypertrophy.
Notably, only miR-29a also correlated with myocardial
ﬁbrosis.
Methods
Further details regarding the methods of this study can be
found in the Online Appendix.
Patient population. Forty-one unrelated patients diag-
nosed with HCM were recruited at the Division of Cardi-
ology, “Federico II” University of Naples, Naples, Italy. The
diagnosis of HCM was based on echocardiographic
demonstration of a hypertrophied, nondilated LV (wall
thickness >15 mm) in the absence of any other cardiac or
systemic disorder producing a comparable grade of hyper-
trophy (16). Classiﬁcation parameters deﬁning HCM status
were those established by the American Heart Association
guidelines (16). No patients were in heart failure. In addi-
tion, 41 healthy age- and sex-matched subjects, recruited
from the Italian blood donor organization AVIS, were
enrolled in the study to serve as controls. None of the
selected healthy subjects had an abnormal blood pressure
response to exercise or a family history of cardiovascular
disease.To determine potential differ-
ences between HCM and left
ventricular hypertrophy (LVH)
consequent to pressure overload,
the current study included 12
high-risk patients with severe sym-
ptomatic aortic stenosis (aortic
valve area [AVA] <1 cm2; body
surface-indexed AVA [iAVA]
<0.6 cm2/m2) (17) recruited at the
“Federico II”University of Naples.
Informed consent was ob-
tained from each patient, and the
study protocol conformed to the
ethical guidelines of the 1975
Declaration of Helsinki, as re-
ﬂected in a priori approval by
the institution’s human research
committee. All subjects under-
went physical examination, elec-
trocardiogram (ECG), 24-hECG
Holter monitoring, TTE and
Doppler studies, and CMR. Pati-
ent characteristics are summarized
in Table 1; TTE and CMR para-
meters are presented in Table 2.
Blood collection and RNA isolation. A 5-ml sample of
peripheral blood was collected in ethylenediaminetetraacetic
acid-containing Vacutainer tubes, processed to eliminate all
blood cells, and aliquots were stored at 80C. Total RNA
was extracted with miRNeasy Mini Kit, following the
manufacturer’s instructions. Each RNA sample was quan-
tiﬁed with a spectrophotometer (NanoDrop 1000, Thermo
Scientiﬁc, Wilmington, Delaware).
Blood and plasma sampling and storage techniques were
the same for patients and controls.
Assessment of circulating miRNAs. Reverse transcription
reactions were performed using the EXIQON miRNA
Reverse Transcription Mercury Universal cDNA synthesis
kit (Exiqon A/S, Vedbaek, Denmark). A PCR System 9700
(Applied Biosystems, Foster City, California) was used to
carry out the reverse transcription PCR reactions. A total of
21 miRNAs previously associated with cardiovascular
disease were selected for investigation: miR-1, -16, -21,
-26a, -27a, -29a, -30a, -126-3p, -126-5p, -133a, -199a-3p,
-199a-5p, -143, -145, -155, -195, -208a, -208b, -214,
-499-3p, and -499-5p. To generate the customized panel of
miRNAs, speciﬁc primer sequences were obtained from the
Exiqon website. miR-208a was also measured with a Taq-
Man assay (Applied Biosystems).
Quantitative real-time polymerase chain reactions were
performed in triplicate for all samples; a 0.2 difference
between detected threshold cycle (Ct) values was considered
acceptable. Ct values were computed with Sequence Detec-
tion System software version 2.4 (Applied Biosystems). The
data were analyzed with automatic settings for assigning the
Table 1 Clinical Characteristics of HCM Patients
HCM Patients Controls
p Value*n Value n Value
Age (yrs) 41 50  13 41 50  10 0.687
Male 41 71% 41 73% 0.797
Signiﬁcant (>30 mm Hg) left ventricular outﬂow tract gradient 10 24.4% 0 0% d
Family history of HCM 11 27% 0 0% d
Family history of sudden death 7 17% 0 0% d
History of syncope 3 7.3% 0 0% d
History of atrial ﬁbrillation 3 7.3% 0 0% d
ICD implant 5 12.2% 0 0% d
Maximum wall thickness >30 mm 4 9.8% 0 0% d
End-stage HCM 1 2.4% 0 0% d
Nonsustained tachycardia 7 17% 0 0% d
Abnormal blood pressure response to exercise 10 24.4% 0 0% d
Pharmacological therapy
No therapy 7 17% 40 97.5% <0.001
Beta-blockers 25 61% 1 2.4% <0.001
Sotalol 2 5% 0 0% 0.479
Verapamil 5 12.2% 0 0% 0.073
Disopyramide 4 9.8% 0 0% 0.134
Mirapexin 1 2.4% 0 0% 1.0
Ivabradine 1 2.4% 0 0% 1.0
ACEIs/AIIRAs 9 22% 1 2.4% 0.013
Diuretics 10 24.4% 1 2.4% 0.016
Statins 11 26.8% 0 0% 0.003
Aspirin/clopidogrel 7 17% 0 0% 0.023
Warfarin 5 12.2% 0 0% 0.074
New York Heart Association functional class
I 27 65.8% ND ND d
II 14 34.2% ND ND d
Mitral regurgitation
Absent 7 17% ND ND d
Mild 20 49% ND ND d
Moderate 12 29% ND ND d
Severe 2 5% ND ND d
Values are mean  SD or %, as indicated. *p Value computed with paired t test for continuous variables and McNemar’s test for categorical variables.
ACEI ¼ angiotensin-converting enzyme inhibitor; AIIRA ¼ angiotensin II receptor antagonist; HCM ¼ hypertrophic cardiomyopathy; ICD ¼ implantable
cardioverter-deﬁbrillator.
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922baseline. The Ct was deﬁned as the fractional cycle number at
which the ﬂuorescence exceeded the given threshold. miRNA
expression levels were normalized to a nonendogenous
synthetic miRNA.
Relative quantiﬁcation was obtained using the 2DDCt
method (18), by which the normalized fold change was
determined as follows: 1) normalization of the Ct of the
target miRNA to that of the reference (spike) for all HCM
patients and healthy individuals (baseline group); and
2) DCtHCM ¼ CtTarget miRNA – CtSpike-in miRNA, and
DCtHealthy¼CtTarget miRNA –CtSpike-in miRNA for all samples.
Then, differential expression (DDCt) of each considered
miRNA was calculated (and expressed as a 2DDCt ratio) by
subtracting mean DCt HCM from mean DCtHealthy (18).
Assessment of hypertrophy. TTE. All echocardiographic
studies were performed using a commercial ultrasound
machine (IE 33, Philips, Andover, Massachusetts) equipped
with an S5-1 5- to 1-MHz phased array transducer.LV end-diastolic and -systolic diameters were measured
in M-mode images and indexed to the body surface
area, according to American Society of Echocardiography
guidelines (19). The extent of LVH (hypertrophy index)
(20) was calculated from the short-axis view at the level of
the mitral valve and papillary muscles by dividing the LV
wall into 4 segments (anterior septum, posterior septum,
lateral free wall, and posterior free wall) and by adding the
maximal wall thickness measured (at both the mitral valve
and papillary muscle level) in each of the 4 ventricular
segments (20). As an additional simple estimate of LVH,
the maximal wall thickness (MWT) measured at any level in
the LV wall was also considered (3). Color Doppler ﬂow
imaging was used for semiquantitative assessment of mitral
regurgitation, which was graded from mild to severe
according to EAE criteria (21). The LV outﬂow tract
gradient was recorded at rest with a 1.9-MHz nonimaging
transducer and was calculated with the simpliﬁed Bernoulli’s
Table 2 TTE and CMR Parameters in HCM Patients
TTE and CMR Parameters
HCM Patients
n Value
Left atrial diameter (mm) 41 47.9  7.2
Left atrial indexed volume (ml/m2) 41 41  19
Left ventricular end-diastolic diameter indexed (mm/m2) 41 25  3
Left ventricular ejection fraction, TTE (%) 41 63.2  7.3
Left ventricular outﬂow tract gradient (mm Hg) 41 18  21
Maximum wall thickness, TTE (mm) 31 21  5
Hypertrophy index, TTE (mm) 41 6  3
Maximum wall thickness, CMR (mm) 21 20  5
Left ventricular mass, CMR (g) 21 158  39
Left ventricular mass index, CMR (g/m2) 21 82  17
Myocardial ﬁbrosis score,* CMR 21 15  13
Values are mean  SD. *Total score of 10 sections/heart.
CMR ¼ cardiac magnetic resonance; HCM ¼ hypertrophic cardiomyopathy; TTE ¼ transthoracic
echocardiography.
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923equation. The LV outﬂow tract obstruction was considered
signiﬁcant at 30 mm Hg. All parameters were measured
on 3 consecutive cycles (selected based on image quality) and
averaged.
CMR. Patients with claustrophobia, arrhythmias (interfering
with ECG gating), or a pacemaker/implanted cardioverter-
deﬁbrillator were excluded from this part of the study (n ¼
20, 49%). The CMR studies were performed using a 1.5-T
magnetic resonance imaging system (Gyroscan Intera, Phi-
lips Medical System, Best, the Netherlands) equipped with
high-performance gradients. LV short-axis images were ob-
tained using 10 slices covering the LV from the apex to the
base for evaluation of LVmass (19). LVmass was normalized
to body surface area. Late gadolinium-enhancement images in
short-axis orientation were acquired for quantiﬁcation of
myocardial ﬁbrosis using a 3-dimensional T1-weighted
inversion recovery turbo gradient echo sequence. To assess
the presence of myocardial ﬁbrosis, a semiquantitative
evaluation was performed by giving a score from 0 to 4,
where 0 ¼ no evidence of ﬁbrosis; 1 ¼ ﬁbrosis between 0%
and 25%; 2 ¼ ﬁbrosis between 25% and 50%; 3 ¼ ﬁbrosis
between 50% and 75%; and 4 ¼ transmural ﬁbrosis (22).
Statistical methods. CLINICAL DATA. Data were analyzed
with SYSTAT version 12.0 (SYSTAT Software Inc., San
Jose, California) and Stata version 11/SE program (College
Station, Texas). Normality assumption was veriﬁed graphi-
cally (i.e., Q plot) and was conﬁrmed using the
Kolmogorov-Smirnov test. The Pearson’s test was per-
formed to evaluate potential correlation between clinical
variables and miRNA levels. Receiver-operating character-
istic (ROC) curves were established for discriminating
patients with or without HCM.
EXPRESSION DATA. Statistical analyses were undertaken
with the Stata version 11/SE program and GenEx software
version 5.0 (Exiqon). Initially, miRNAs with a Ct cutoff
39 were ﬁltered out to minimize any potential instrument
background noise that could have interfered with themeasurements. Quantitative variables are given as means 
SD and interquartile ranges. Normality assumption was
veriﬁed graphically (i.e., Q plot) and was conﬁrmed using
the Kolmogorov-Smirnov test. TaqMan quantitative real-
time polymerase chain reaction assays were done in tripli-
cate with the synthetic spiked-in miRNA across all samples.
A mean Ct for the synthetic miRNA and all samples was
calculated. A 2-sided t test was conducted to determine
which miRNAs were differently expressed. Paired t test and
McNemar’s test were used for continuous and categorical
variables, respectively, to compare cases and control in
Table 1. Statistical signiﬁcance was deﬁned as p < 0.05 for
all tests. All p values are 2-sided.Results
Circulating miRNA levels in HCM patients. Plasma
miRNA levels were assessed in 41 HCM patients and
41 age- and sex-matched healthy controls. Among the 21
miRNAs analyzed, 12 were found signiﬁcantly increased
in HCM plasma. These were: miR-27a, -199a-5p, -26a,
-145, -133a, -143, -199a-3p, -126-3p, -29a, -155, -30a,
and -21 (Fig. 1). No signiﬁcant differences were observed
for miR-499-5p, -195, or -126-5p, whereas miR-214, -16,
and -1 tended to be decreased, although not signiﬁcantly.
The cardiac-speciﬁc miR-208b was detected in only 13
HCM patients, whereas miR-499-3p was not detected
in any of the samples. miR-208a was detected in only
12 HCM patients with both Exiqon and TaqMan
analyses.
To determine the validity of the results obtained in HCM
patients, we measured the same miRNAs in another type of
cardiac hypertrophy: concentric LVH induced by severe
aortic valve stenosis. We found a similar trend for only 5
miRNA (miR-21, -26a, -27a, -30a, and -133a) (Online
Fig. 1), suggesting speciﬁc miRNA signatures for the 2
pathological conditions.
ROC analysis. ROC curves for each of the miRNAs
analyzed were generated. Eight of the 12 signiﬁcantly
increased miRNAs had an optimal area value under the
curve (AUC) >0.70 (Fig. 2).
Correlation of miRNA level with LV hypertrophy and
myocardial ﬁbrosis. After we had determined the differ-
ential miRNA expression pattern, we examined whether
any miRNA was correlated (either directly or inversely)
with clinical prognostic variables of HCM (Tables 1
and 2). To be noted, the clinical variables considered and
the measured miRNAs were all normally distributed. We
found signiﬁcantly positive correlation coefﬁcients for miR-
29a and hypertrophy, as deﬁned by 4 of the parameters
tested (MWT determined by both TTE and CMR, LV
mass, and the hypertrophy index) (Table 3, Online Fig. 2).
miR-27a and -199a-5p correlated positively with hyper-
trophy when deﬁned as LV mass or as LV mass index
evaluated by CMR; however, no correlation with TTE
parameters was found for either of these 2 miRNAs.
Figure 1 Relative Expression of Circulating miRNAs
Individual value plots of the variability and differences in the plasma level of each microribonucleic acid (miRNA) in healthy individuals (right of each plot) and patients with
hypertrophic cardiomyopathy (HCM) (left of each plot). Numbers represent p values obtained with 2-sided t test of miRNA expression in the HCM versus healthy groups.
A crossbar on each plot indicates the mean expression level for each group.
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924In addition, signiﬁcant correlations were found for miR-21
and -155 with the parameters MWT (as assessed by CMR)
and hypertrophy index. Importantly, among miRNA associ-
ated with LV mass (i.e., miR-27a, -29a, and -199a-5p), only
miR-29a correlated positively with myocardial ﬁbrosis, as
assessed with CMR (r ¼ 0.691, p ¼ 0.003) (Online Fig. 3).To evaluate potential synergic effects between miR-21
and -29ad2 ﬁbroblast-associated miRNAs that were
signiﬁcantly altered in HMCdan estimated model was
used, but no signiﬁcant results were found. In addition, no
signiﬁcant interactions were found between circulating levels
of miRNAs and any of the drugs administered to the
Figure 2 AUC Analysis of Receiver-Operating Characteristics
The area under the curve (AUC) (values given on the graphs) for miRNAs with signiﬁcantly increased circulating levels were computed for the HCM group. Abbreviations
as in Figure 1.
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925patients (including beta-blockers, verapamil, disopyramide,
angiotensin-converting enzyme inhibitors/angiotensin II
receptor antagonists, diuretics, statins, and aspirin/clopi-
dogrel), which could also be affected by the small sample
size.Discussion
We have assessed the circulating levels of 21 miRNAs
involved mostly in cardiac remodeling in patients with
HCM, a primary form of cardiomyopathy. Our aim
was to characterize the circulating miRNA proﬁle in
HCM patients and identify the determinants of anyTable 3 Pearson Correlation Coefﬁcients of Signiﬁcantly Increased m
LVEDI, TTE MWT, TTE
r Value p Value r Value p Value r Va
miR-29a 0.197 0.146 0.463 0.005 0.
miR-27a 0.030 0.824 0.126 0.469 0.
miR-199a-5p 0.012 0.932 0.117 0.504 0.
miR-21 0.143 0.294 0.291 0.090 0.
miR-155 0.088 0.519 0.294 0.086 0.
miR-126-3p 0.078 0.565 0.048 0.783 0.
miR-133a 0.103 0.451 0.164 0.346 0.
miR-30a 0.107 0.432 0.006 0.973 0.
miR-26a 0.019 0.889 0.321 0.060 0.
miR-199a-3p 0.029 0.839 0.172 0.347 0.
miR-145 0.170 0.211 0.106 0.546 0.
miR-143 0.115 0.397 0.207 0.233 0.
Values are Pearson correlation coefﬁcient (r) and relative computed p value. Signiﬁcant values are hig
segments in short-axis view at the mitral valve and papillary muscle level.
LVEDI ¼ left ventricular end-diastolic diameter index; LVMI ¼ left ventricular mass index; miRNA ¼ mdifferential expression versus age- and sex-matched
healthy individuals.
We found that levels of the majority of the analyzed
miRNAs (12 of 21) were signiﬁcantly increased in the
plasma of HCM patients; moreover, 8 of these 12 miRNAs
had an ROC curve that distinguished the HCM group from
the healthy group (AUC >0.70). In particular, among the
“myo-miRNAs” (23), miR-133a was increased, miR-499
could not be measured at all, and miR-208a and -208b
were increased in only a subset of patients. The miRNAs
that increased the most, however, were those involved in the
regulation of angiogenesis and vascular cell differentiation.
Within this group, the increased level of the miR-143/145iRNAs and Prognostic Clinical Parameters of HCM
MWT, CMR LVMI, CMR Hypertrophy Index, TTE*
lue p Value r Value p Value r Value p Value
412 0.021 0.325 0.069 0.475 0.001
281 0.125 0.380 0.032 0.186 0.227
151 0.419 0.421 0.017 0.087 0.576
406 0.023 0.176 0.334 0.346 0.021
356 0.049 0.325 0.069 0.308 0.042
255 0.167 0.294 0.102 0.086 0.425
181 0.329 0.041 0.822 0.175 0.230
157 0.398 0.302 0.093 0.030 0.848
315 0.085 0.292 0.105 0.252 0.099
113 0.552 0.080 0.673 0.150 0.348
218 0.238 0.199 0.276 0.161 0.296
266 0.148 0.217 0.232 0.242 0.114
hlighted in bold. *Sum of maximum wall thickness (MWT) measured in each of 4 left ventricular
icroribonucleic acid; other abbreviations as in Table 2.
Roncarati et al. JACC Vol. 63, No. 9, 2014
Circulating MicroRNAs in Hypertrophic Cardiomyopathy March 11, 2014:920–7
926clusterda miRNA family mostly expressed in smooth
muscle cells (24–26)dis surprising. These miRNAs have
been shown to be expressed also during cardiac differentia-
tion in vitro and cardiac development, although only tran-
siently (27). Thus, the surge in plasma of these miRNAs
reﬂects either an activation in cardiomyocytes of the fetal
gene programda hallmark of cardiac hypertrophy (28)dor
signiﬁcant vasculogenesis in the HCM heart (29). We
tend to favor the second hypothesis, because in a model
of miR-143/145 transgenesis generated in our laboratory
(25), we could not detect expression of this cluster in
cardiomyocytes during development.
The most striking ﬁnding of this study is the correlation
between miR-29a and cardiac hypertrophy, as measured by
assessing 4 parameters with 2 independent techniques, and
ﬁbrosis, as measured with CMR, in patients with HCM.
miR-29 is produced mostly by ﬁbroblasts, and its family
members are key regulators of ﬁbrosis, modulating mRNA
levels of collagen and other extracellular matrix genes
(30–32). In addition, this miRNA was found to be a key
player in liver (33), pulmonary (34), and kidney ﬁbrosis (35)
and in systemic sclerosis (36). Moreover, miR-29a was up-
regulated along with miR-29c in an animal model of
physiological cardiac adaptation to exercise training (37), in
contrast with a previous pattern reported for miRNAs
associated with pathological hypertrophy (38). To date, no
data are available on miR-29a in HCM, and our study is, to
our knowledge, the ﬁrst to point out an association between
circulating miR-29 and the presence of ﬁbrosis in HCM.
Interestingly, the association of miR-29a with myocardial
ﬁbrosis seems to be speciﬁc for HCM in that its circulating
level in patients with severe aortic stenosis was not increased
relative to the control group.
We also found that in contrast with miR-29a, another
miRNA involved in cardiac ﬁbrosis, miR-21 (39), although
also signiﬁcantly increased in HCM plasma, did not corre-
late with the degree of hypertrophy or with the extension of
myocardial ﬁbrosis.
High-sensitivity cardiac troponin T (hs-cTnT) and brain
natriuretic peptide (BNP) have been recently proposed as
biomarkers of ﬁbrosis in HCM patients (40). In comparison
with hs-cTnT and BNP, miRNAs show a more signiﬁcant
AUC. Also, although hs-cTnT is correlated with the extent
of ﬁbrosis, BNP is associated with LV overload rather than
myocardial ﬁbrosis, and therefore does not seem to be
a direct marker of ﬁbrosis (40).
Another signiﬁcant result is that myo-miRNAs, as well
as other cardiovascular miRNAs, can be released into the
bloodstream even when there is no ongoing myocardial
damage. Myo-miRNAs have already been measured in the
plasma of patients with myocardial infarction (12). In the
present study, we found that the circulating level of some
of these miRNAs can increase also when there is cardiac
hypertrophy and ﬁbrosis without any clinically evident acute
cellular damage. In this case, the circulating levels reﬂect
mostly miRNAs secreted from intact cells rather thanreleased from damaged cells. This holds true also for
nonmuscle-speciﬁc miRNAs, and in our view, this indicates
that an organ undergoing stress tends to release miRNAs
into the bloodstream from all cell types of which it is
composed.
Finally, the circulating levels of miRNAs transcribed as an
isocluster, such as miR-1 and miR-133a, were not neces-
sarily up-regulated together, indicating that the members of
multicistronic miRNA genes can be subject to different
intracellular metabolic pathways: some may be released from
cells, whereas others have an intracellular fate.
Study limitations. Hitherto, there are no studies in the
literature on the mechanisms of miRNA release and on their
metabolism once secreted into the extracellular space. This
lack of knowledge on miRNA biology hinders the assess-
ment of circulating miRNAs. Moreover, the method used in
this study for assessing circulating miRNA levels does not
distinguish between miRNAs transported by exosomes and
those transported by plasma proteins; it is thus possible that
we did not efﬁciently measure exosome-bound miRNAs.
Future studies are undoubtedly needed to clarify these
points. In addition, we assumed that the miRNAs measured
in the bloodstream were produced mainly by the heart. It is
in theory possible that secondary effects on other organs or
tissues induced by primary cardiomyopathy are reﬂected in
an increased production of miRNAs. For instance, the surge
in miR-29a could be due to damage of the aortic arch
(31,32). However, our patient population was selected on
the basis of being free from major complications in organs
other than the heart. Thus, it is highly probable that plasma
levels mirrored the extent of miRNA biogenesis within the
heart.Conclusions
A circulating miRNA proﬁle distinguishes HCM patients
from healthy individuals. Three signiﬁcantly up-regulated
miRNAsdmiR-27a, -29a, and -199a-5pdcorrelated with
LV mass, whereas only miR-29a correlated with ﬁbrosis.
The circulating miRNA proﬁle of this type of cardiomy-
opathy was also different from that of hypertrophy because
of aortic stenosis, indicating that circulating proﬁles may be
disease speciﬁc. This is the ﬁrst instance in which a circu-
lating miRNA has been shown to correlate with myocardial
ﬁbrosis in a clinical setting, identifying miR-29a as
a potential biomarker for myocardial remodeling assessment
in HCM.Reprint requests and correspondence: Dr. Sandro Betocchi,
Department of Internal Medicine, Cardiovascular & Immunolog-
ical Sciences, Federico II University, Via S. Pansini 5, 80131,
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APPENDIX
For supplemental methods information as well as a supplemental table and
ﬁgures, please see the online version of this article.
